# Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

> **NCT01306045** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 647 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Small Cell Lung
- Carcinoma, Thymic

## Interventions

- **DRUG:** AZD6244
- **DRUG:** MK-2206
- **DRUG:** Lapatinib
- **DRUG:** Erlotinib
- **DRUG:** Sunitinib
- **PROCEDURE:** Molecular Profiling

## Key facts

- **NCT ID:** NCT01306045
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02-08
- **Primary completion:** 2014-02-12
- **Final completion:** 2024-07-17
- **Target enrollment:** 647 (ACTUAL)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01306045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01306045, "Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01306045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*